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1. Introduction 
Immunological reactivity results from differences between the transplant host and donor 
for cell surface determinants known as histocompatibility antigens. Histocompatibility 
antigens that provoke the most severe transplant reactions are encoded by a series of 
genes that reside in a discrete chromosomal region termed the major histocompatibility 
complex (MHC) (Amos 1968). Genes of the human leukocyte antigen (HLA) system 
encode a complex array of histocompatibility molecules that play a central role in immune 
responsiveness and in determining the outcome of hematopoietic stem cell 
transplantation (HSCT) (Beatty, Anasetti et al. 1993; Petersdorf, Longton et al. 1995). The 
primary goal of histocompatibility testing for patients who are undergoing HSCT is the 
identification of a suitable HLA-matched donor to reduce the risk of post-transplant 
complications, which may result from HLA incompatibility. The extensive polymorphism 
of the HLA system, however, makes the selection of a comprehensively, optimally-
matched donor a challenging endeavor, particularly when donors outside of the patient’s 
immediate family are sought. If a suitable donor is not found, clinicians need to explore 
the possibility of permissive HLA mismatches. 
Haploidentical HSCT is curative treatment for patients lacking an HLA-compatible donor or 
cannot wait until a suitable donor can be found (Reisner, Kapoor et al. 1981; Buckley, Schiff 
et al. 1999). Haploidentical HSCT is usually employed with T-cell depletion or positive 
selection of CD34+ cells to avoid severe graft-versus-host disease (GVHD) (Aversa, Tabilio et 
al. 1994). However there are disadvantages, such as potential for graft failure, fatal 
opportunistic infections, and relapse of the treated malignancy. To deal with those 
problems, T-cell “replete” haploidentical HSCT have been performed by researchers in 
Japan (Ichinohe, Uchiyama et al. 2004). These are based on the hypothesis that long-term 
maternal microchimerism (MMc) is associated with acquired immunologic 
hyporesponsiveness to non-inherited maternal antigen (NIMA) (Andrassy, Kusaka et al. 
2003; Dutta, Molitor-Dart et al. 2009). T-cell replete HSCT, without GVHD, could be 
accomplished by using this phenomenon of feto-maternal tolerance. Unfortunately, graft 
rejection and hyperacute GVHD have been reported in HSCT from NIMA-mismatched 
siblings, despite detecting of MMc (Okumura, Yamaguchi et al. 2007). Therefore, 
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development of a predictable method for GVHD in NIMA-mismatched HSCT is needed. We 
have produced a novel prediction assay, using MLR-ELISPOT (mixed lymphocyte reaction; 
enzyme-linked immunospot) assay, for detecting reactivity to NIMA (Araki, Hirayama et al. 
2010). In this review, we discuss acute GVHD in T-cell depleted and T-cell replete HSCT, the 
role of major and minor histocompatibility in NIMA tolerance, and prediction of acute 
GVHD in T-cell replete HSCT via our model assay. 
2. Minor histocompatibility antigens in mouse and human  
Alloantigens can be divided into major histocompatibility complex (MHC) antigen and 
minor histocompatibility antigen (MiHA), the former responsible for eliciting the strongest 
immune responses to allogeneic tissues. The MHC is referred to as the H-2 complex in mice 
and as the HLA complex in humans. 
MHC identity of donor and host is not the sole factor determining immunological reactivity 
in HSCT. When transplantation is performed in an unrelated setting (MUD, matched-
unrelated donor), even if MHC antigens of donor are identical to recipient, considerable 
transplant reactions may occur because of differences at various minor histocompatibility 
loci. MiHAs are capable of eliciting cellular alloimmune responses in vitro and in vivo. They 
are peptides derived from polymorphic proteins. Their immunogenicity arises as a result of 
their presentation in the context of MHC class I or II, where they are recognized by 
alloreactive MHC-restricted T cells. The most important immune reactions elicited by in 
vivo alloreactivity to MiHA are graft rejection and GVHD. 
To date, human MiHAs have not been fully characterized. Some murine MiHAs have been 
compared with human counterparts though (see, HY antigens in Table 1). Immunological 
targeting of HY proteins results in a relatively high incidence of acute GVHD when male 
recipients receive HSCT from female donors (Stern, Passweg et al. 2006). While 
approximately one third of the known MiHAs are encoded in Y chromosome, many MiHAs 
are located on autosomal chromosomes (Table 1). Genetic linkage analysis has been used to 
define the genomic regions encoding the MiHAs (Akatsuka, Nishida et al. 2003; de Rijke, 
van Horssen-Zoetbrood et al. 2005). With these more recent advanced techniques, more 
human MiHAs epitopes have been identified (van Bergen, Kester et al. 2007; Kawase, 
Akatsuka et al. 2007; Tykodi, Fujii et al. 2008; Griffioen, van der Meijden et al. 2008; 
Spaapen, Lokhorst et al. 2008; Spaapen, de Kort et al. 2009; Kamei, Nannya et al. 2009; 
Stumpf, van der Meijden et al. 2009; Bleakley, Otterud et al. 2010; Van Bergen, Rutten et al. 
2010; Sellami, Kaabi et al. 2011). 
MiHA Species Chromosome Gene MHC restriction 
Tissue 
specificity 
References 
Y chromosome 
HY Mouse Y Smcy H-2Kk, H-2Db Ubiquitous 
(Markiewicz et 
al. 1998) 
HY Mouse Y Uty H-2Db Ubiquitous 
(Greenfield et al. 
1996) 
HY Mouse Y Dby H-2Ab, H-2Ek Ubiquitous (Scott et al. 2000) 
SMCY Human Yq11 JARID1D
HLA-A*02:01, 
B*07:02 
Ubiquitous 
(Wang et al. 
1995) 
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MiHA Species Chromosome Gene MHC restriction 
Tissue 
specificity 
References 
UTY Human Yq11 UTY HLA-B8, B60 Ubiquitous (Vogt et al. 2000) 
DBY Human Yq11 DDX3Y 
HLA-B*27:05, 
DRB1*15:01, DQ5
Hematopoietic (Zorn et al. 2004) 
DFFRY Human Yq11.2 USP9Y HLA-A*01:01 Ubiquitous 
(Pierce et al. 
1999) 
RPS4Y Human Yp11.3 RPS4Y1 
HLA-B*52:01, 
DRB3*03:01 
Ubiquitous 
(Spierings et al. 
2003) 
TMSB4Y Human Yq11.221 TMSB4Y HLA-A*33:03 Ubiquitous 
(Torikai et al. 
2004) 
Autosomal chromosome 
H3 Mouse 2 Zfp106 H-2Db Ubiquitous 
(Zuberi et al. 
1998) 
H4 Mouse 7 Emp3 H-2Kb Ubiquitous 
(Luedtke et al. 
2003) 
H7 Mouse 9 D9Mit182 H-2Db Ubiquitous 
(Perreault et al. 
1996) 
H13 Mouse 2 
47c1 
cDNA 
H-2Db Ubiquitous 
(Mendoza et al. 
1997) 
H28 Mouse 3 NS1178 H-2Kb Ubiquitous 
(Malarkannan et 
al. 2000) 
H46 Mouse 7 Il4i1 H-2Ab Hematopoietic
(Sahara et al. 
2003) 
H47 Mouse 7 H47 H-2Db Ubiquitous 
(Mendoza et al. 
2001) 
H60 Mouse 10 Rae1 H-2Kb Hematopoietic (Choi et al. 2001) 
HA-1 Human 19p13.3 HMHA1 
HLA-A*02:01, 
A*02:06, B60 
Hematopoietic
(Mommaas et al. 
2002) 
HA-2 Human 7p13-p11.2 MYO1G HLA-A*02:01 Hematopoietic
(den Haan et al. 
1995) 
HA-3 Human 15q24-q25 AKAP13 HLA-A*01:01 Ubiquitous 
(Spierings et al. 
2003) 
HA-8 Human 9p24.2 KIAA0020 HLA-A*02:01 Ubiquitous 
(Brickner et al. 
2001) 
HB-1 Human 5q31.3 HMHB1 
HLA-B*44:02, 
B*44:03 
B-cell 
(Dolstra et al. 
1999) 
ACC-1, 2 Human 15q24.3 BCL2A1 
HLA-A*24:02, 
B*44:03 
Hematopoietic
(Akatsuka et al. 
2003) 
UGT2B17 Human 4q13 UGT2B17
HLA-A*02:06, 
A*29:02, B*44:03 
Ubiquitous 
(Murata et al. 
2003) 
LRH-1 Human 17p13.3 P2RX5 HLA-B*07:02 Hematopoietic
(de Rijke et al. 
2005) 
CTSH Human 15q25.1 CTSH 
HLA-A*31:01, 
A*33:03 
Ubiquitous 
(Torikai et al. 
2006) 
LB-
ECGF1-1H 
Human 2q13.33 ECGF1 HLA-B*07:02 Hematopoietic
(Slager et al. 
2006) 
PANE1 Human 22q13.2 CENPM HLA-A*03:01 Hematopoietic
(Brickner et al. 
2006) 
SP110 Human 2q37.1 SP110 HLA-A*03:01 Hematopoietic
(Warren et al. 
2006) 
Table 1. Minor histocompatibility antigens in mouse and human 
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3. Acute GVHD in T-cell depleted or replete haploidentical transplantation 
Haploidentical HSCT has made progress over the past 30 years and has become a feasible 
option for patients without an HLA-identical sibling donor. This is especially true for 
reconstitution of immunity in infants with severe combined immunodeficiency, where use 
of rigorously T-cell depleted marrow has been quite successful (Buckley, Schiff et al. 
1999). In early trials of haploidentical HSCT, ex vivo T-cell depletion method of 
haploidentical bone marrow cells was an effective method reported by Reisner et al 
(Reisner, Kapoor et al. 1981). This procedure without immunosuppressive prophylaxis 
allowed durable engraftment rate about 75% with acceptable incidence of acute GVHD 
(36%) in patients with severe combined immunodeficiency (Buckley, Schiff et al. 1999). 
However, its application to haploidentical HSCT for leukemia was less encouraging due 
to the high incidence of graft failure (30%) and infectious complications (80%) (O'Reilly, 
Keever et al. 1987). In a trial from the University of Perugia, the use of T-cell depletion in 
combination with a high dose of stem cells overcame graft rejection as well as acute 
GVHD (Aversa, Tabilio et al. 1994). Improved positive selection of CD34+ cells was 
accomplished by depletion of B cells, in addition to T cells, which resulted in a lower 
incidence of EBV-associated lymphoproliferative disease (LPD) (Aversa, Terenzi et al. 
2005). Another method using ex vivo T-cell depletion of bone marrow cells with anti-T-
cell monoclonal antibodies, followed by treatment with cyclosporine and ATG, was 
encouraging for the use of haploidentical marrow (Henslee-Downey, Abhyankar et al. 
1997). Over 95% durable engraftment and low incidence of acute GVHD (13%) were 
obtained, and accompanied with an acceptable relapse rate (31%) (Mehta, Singhal et al. 
2004). Although these various depletion techniques achieved benefit, to truly achieve 
more acceptable results, further improvement is necessary to address the high rate of 
malignancy relapses, acute and chronic GVHD, and otherwise, treatment-related 
morbidity and mortality. 
As an alternative to ex vivo T-cell depletion, in vivo T-cell depletion methods have been 
undertaken for improving relapse rates and treatment-related mortality. Lu et al. from 
Peking University described the transplantation of combination of G-CSF-primed bone 
marrow and peripheral blood with intensive immunosuppression using ATG (Lu, Dong et 
al. 2006). Although the cumulative incidence of grade II to IV acute GVHD was 
comparatively high, 40%, two-year incidences of relapses and treatment-related mortality 
were low, 22% and 18%, respectively. More recently, Huang et al., in the same group 
reported encouraging clinical outcomes in 250 patients with haploidentical HSCT. The 3-
year of leukemia free survival in standard and high-risk AML was 70.7% and 55.9%, 
respectively, and 59.7% and 24.8% for ALL (Huang, Liu et al. 2009). In another approach, 
Rizzieri et al. reported that alemtuzumab was used for in vivo depletion of both recipient 
and donor T-cells, in order to allow for more reliable engraftment and decreased GVHD 
(Rizzieri, Koh et al. 2007). 
Sibling-related NIMA-mismatched transplantation, as an approach to T-cell replete 
haploidentical HSCT, was introduced as an alternative to ex vivo or in vivo T-cell depleted 
haploidentical HSCT. Van Rood et al. first showed that the incidence of acute GVHD was 
lower in patients who received T-cell replete grafts from an NIMA-mismatched sibling than 
those from non-inherited paternal antigen (NIPA) -mismatched sibling (van Rood, Loberiza 
et al. 2002). This indicated that the presence of immunological hyporesponsiveness against 
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NIMA in haploidentical transplantation could be important for prevention of GVHD and 
other immunologic comorbidities. Ichinohe et al. also showed that T-cell replete 
haploidentical HSCT from NIMA-mismatched family donor was feasible in selected patients 
with poor-risk hematologic malignancies using standard GVHD prophylaxis (Ichinohe, 
Maruya et al. 2002). However, 10% of patients still experienced severe acute GVHD, and 
there was not a useful method to predict acute GVHD in these patients. Thus, both T-cell 
depleted and T-cell replete haploidentical HSCT have benefits and drawbacks (Table 2). The 
problems of T-cell depleted HSCT were relatively high rate of graft failure, delayed immune 
reconstitution resulting in infections, and relapse of malignancies (Henslee-Downey, 
Abhyankar et al. 1997; Guinan, Boussiotis et al. 1999; Mehta, Singhal et al. 2004; Lu, Dong et 
al. 2006; Huang, Liu et al. 2009). On the other hand, the problems of T-cell replete 
haploidentical HSCT were relatively high rates of acute GVHD and treatment-related 
mortality (Ichinohe, Maruya et al. 2002; van Rood, Loberiza et al. 2002; Kanda, Ichinohe et 
al. 2009). Therefore, if an effective method to predict GVHD is available, T-cell replete 
haploidentical HSCT may be feasible with relative safety; lower risk of GVHD, lower risk of 
infections, and lower risk of malignancy relapse. 
 
Type of 
HSCT 
Age Source ATG
Acute GVHD
(Grade II-IV)
Graft 
failure
TRM Relapse DFS 
T-cell depleted 
(Ex vivo) 0-33 BM + 5-8 % 3-5 % 17-47 % 11-25 % 35-38 % 
(In vivo) 16-25 BM ± PB + 13-46 % 0-13 % 22-51 % 18-31 % 18-64 % 
T-cell replete 
(NIMA/ 
Mother) 
15-28 BM or PB -* 41-58 % 0-20 % 18-57 % 6-25 % 30-81 % 
(NIPA/ 
Father) 
17-20 BM -* 55-63 % 13-29 % 36-45 % Unknown 24-44 % 
*More than 90% of patients were not used. 
Abbreviations: ATG, anti-thymocyte globulin; TRM, treatment-related mortality; DFS, disease-free 
survival; BM, bone marrow; PB, peripheral blood. 
Table 2. Frequency of acute GVHD in T-cell depleted and T-cell replete HSCT 
4. Tolerance to non-inherited maternal antigen in murine studies 
Maternal cells and fetal cells, most notably lymphocytes, are known to reciprocally traffic 
across the placenta during fetal development (Hall, Lingenfelter et al. 1995; Lo, Lo et al. 
1996), and can result in life-long MMc in the offspring (Maloney, Smith et al. 1999). Prenatal 
exposure to NIMA affects the neonate’s developing immune system, producing some 
tolerization to the non-inherited MHC components. There have been several previously 
reported investigations of NIMA (Burlingham, Grailer et al. 1998; Andrassy, Kusaka et al. 
2003), as illustrated in Figure 1.  
www.intechopen.com
 
Histocompatibility 
 
150 
 
A-Left, C57BL/6 (B6) males (H-2b/b) were mated with (B6 x DBA/2) F1 female (H-2b/d), thus exposing 
the H-2b/b offspring in utero and via breast feeding to NIMAd antigens. Right, (B6 x DBA/2) F1 males 
were mated with B6 female, creating H-2b/b backcross offspring that had not been exposed to “d” as 
reported by Andrassy et al. B-I-Left, B10.BR males (H-2k) were mated with (B10.D2 x B10) F1 females 
(H-2d/b), thus exposing the H-2d/k type offspring to NIMAb, and H-2b/k type offspring to NIMAd Right, 
(B10.D2 x B10) F1 males (H-2d/b) were mated with B10.BR females (H-2k), creating the controls; both H-
2d/k and H-2b/k type offsprings that had not been exposed to b and d, respectively. These mice have B10 
background, in other words, their MiHA (i.e. H-4, H-13, H-60, etc) are matched, and H-2 antigens are 
mismatched in both class I and II. B-II-Left, C3H males (H-2k) were mated with CB (BALB/c x B6) F1 
females (H-2d/b), thus exposing the H-2d/k type offspring to NIMA b antigens and MiHA (NIMAH-
2b+MiHA), and H-2b/k type offspring to NIMAH-2d+MiHA. Right, CB F1 males (H-2d/b) were mated with C3H 
females (H-2k), creating the controls; both H-2d/k and H-2b/k type offspring that had not been exposed to 
H-2b+MiHA and H-2d+MiHA, respectively. C, Breeding pattern were summarized in terms of major 
and minor histocompatibility Ags to NIMA. 
Fig. 1. Murine models for non-inherited maternal antigens. 
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In addition, maternal cells and MHC/HLA proteins are ingested by the baby during 
nursing, possibly stimulating oral tolerance (Verhasselt, Milcent et al. 2008; Aoyama, 
Koyama et al. 2009). The clinical benefits of developmentally acquired tolerance to NIMA 
were first noted by Owen et al. more than 50 years ago (Owen, Wood et al. 1954). Since then, 
tolerogenic effects of NIMA have been documented at both T- and B-cell levels in a variety 
of clinical settings (Claas, Gijbels et al. 1988; van Rood and Claas 1990; Burlingham, Grailer 
et al. 1998). Presence of feto-maternal tolerance was anticipated due to the presence of MMc 
(Andrassy, Kusaka et al. 2003), and the concept has been used in clinical studies (Ichinohe, 
Uchiyama et al. 2004). On the basis of this hypothesis, several transplantation centers in 
Japan have performed clinical trials to test the feasibility of HLA-haploidentical HSCT from 
a NIMA mismatched relative, without using either T-cell depletion or intensive post-
transplant immunosuppression (Ichinohe, Uchiyama et al. 2004; Kanda, Ichinohe et al. 2009). 
Persistent MMc is associated with antigen-specific suppression of the associated T-cell 
responses (van Rood, Loberiza et al. 2002). With the help of highly sensitive polymerase 
chain reaction (PCR)-based techniques, long-term MMc can be detected from the peripheral 
blood, or various tissues including liver, skin, and thyroid gland (Ichinohe, Maruya et al. 
2002). Several investigators have suggested the association of long-term MMc with the 
development of tolerance to NIMA (Kodera, Nishida et al. 2005). Thus, successful NIMA-
mismatched haploidentical HSCT have been performed confirming long-term MMc as an 
indication of tolerance induction, in agreement with the correlation between MMc and 
tolerance in mice, which has been described recently (Dutta, Molitor-Dart et al. 2009). 
However, in some individuals unsuccessful NIMA-mismatched haploidentical HSCT have 
occurred, when the concept of MMc would have predicted otherwise. 
The relevance of MiHA in tolerance to NIMA has not been reported. In both MHC-identical 
and MHC-haploidentical transplants, MiHA alloreactivities may be induced (Verdijk, 
Kloosterman et al. 2004). Therefore, maintaining the focus on the tolerance-induction of 
NIMA to MHC may have greater clinically relevance. In accord with this, we have shown 
differences in the NIMA tolerogenic effect in different individuals, divided into high 
responder (HR) or low responder (LR) categories, depending on the magnitude of the MLR 
of donor against recipient NIMA (Araki, Hirayama et al. 2010). The magnitude of the 
responses was associated with the extent of regulatory T cells (Treg) and Foxp3 expression 
in MHC-mismatched, MiHA-matched HSCT (Figure 2). This, with other reports, describe 
that Treg mediate tolerance to NIMA (Aluvihare, Kallikourdis et al. 2004; Matsuoka, 
Ichinohe et al. 2006). Survival rates and GVHD clinical scores of NIMA-exposed LR mice 
were significantly better than those of NIMA-exposed HR mice (Figure 3). Moreover, the 
level of MMc was correlated with the tolerogenic effect of the NIMA (Araki, Hirayama  
et al. 2010). 
The mouse MiHA loci confers a wide range of immunogenicity, ranging from weakly to 
strongly immunogenic (Roopenian, Choi et al. 2002). Several studies have provided evidence 
that GVHD could be caused by only a limited number of mouse MiHA as described above 
(Choi, Yoshimura et al. 2001; Yang, Jaramillo et al. 2003; Eden, Christianson et al. 1999). The 
specific MiHA immunodominance was manifested on genetically varied backgrounds among 
B10, BALB/c, and DBA/2 strains (Sanderson and Frost 1974; Mendoza, Paz et al. 1997;  
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We have shown a difference of proliferative response to NIMA in NIMA-exposed and NIMA-non-exposed 
mice. The mice were classified into two groups by MLR, based on their reactivity to NIMA; the high 
responder (HR ≥ mean+1SD in NIMA-nonexposed) or the low responder (LR < mean+1SD) group (Araki, 
Hirayama et al. 2010). Upper, The percentage of CD4+CD25+ cells in CD4+ cell population was analyzed by 
flow cytometry. Lower, The relative expression of Foxp3 compared with GAPDH is presented as the mean 
+ SE. Samples were obtained 21 days after GVHD induction from recipients injected with cells from 
NIMA-exposed LR, HR, and NIMA-nonexposed mice (n=5 in each group). *p<0.05. 
Fig. 2. Regulatory T cells and Foxp3 expression correlated with reactivity to MHC. 
Malarkannan, Horng et al. 2000). Previously, there has been no report distinguishing the 
reactivities of MHC and MiHA from the tolerogenic effect of NIMA. We have proposed to 
classify the murine models of NIMA based on major and minor histocompatibility antigens 
to NIMA (Hirayama and Azuma 2011) (Figure 1C). In our study, all B10 congenic mice were 
used as the former NIMA model, “major only” (Figure 1B-I), and those MiHA had matched 
entirely in this system (Araki, Hirayama et al. 2010). On the other hand, the previous model 
(Andrassy, Kusaka et al. 2003; Matsuoka, Ichinohe et al. 2006) (Figure 1A) and the latter our 
model, “major + minor” (Figure 1B-II) were mismatched at both H-2 and MiHA. Therefore, 
we need to consider an influence of both major and minor histocompatibility when NIMA 
tolerance is evaluated (Hirayama and Azuma 2011) (Figure 1C). 
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A, The survival of sublethally irradiated recipient B10 female mice injected with vehicle (□, n = 14), cells 
from NIMA-exposed LR mice (H-2d/k, NIMAb) (○, n = 30), HR mice (NIMAb) (△, n = 33), NIMA-
nonexposed mice (H-2d/k, NIMAnone) (●, n = 39), and allogeneic B10.D2 mice (■, n =14). B, The GVHD 
clinical score was determined in recipients injected with cells from NIMA-exposed LR mice (○, n = 48), 
HR mice (△, n = 45), allogeneic mice (●, n = 47), and vehicle (□, n = 12). The degree of clinical GVHD 
was assessed by the scoring system that incorporates five clinical parameters: weight loss, posture, 
activity, fur texture, and skin integrity, grading from 0 to 2 for each parameter. A clinical index was 
subsequently generated by summation of the five criteria scores (maximum index=10). Data are 
expressed as the means + SE of individual animals. **p<0.01, *p<0.05. 
Fig. 3. Two distinct reactivities to H-2 in NIMA-exposed mice resulted in differences in 
GVHD induction. 
 
A, ELISPOT assay combining with MLR (MLR-ELISPOT) is a sensitive functional assay to detect 
alloreactivity for both major and minor histocompatibility antigens in mice. B, The IFN-γ-producing 
ability before GVHD induction was presented by MLR-ELISPOT. Peripheral blood mononuclear cells 
from NIMA-exposed LR mice (H-2d/k, NIMAb, n=8), HR mice (n=7), and nonexposed mice (n=6) were 
stimulated with B10 mice peripheral blood mononuclear cells. Data are expressed as the means + SE of 
individual animals. *p<0.05. 
Fig. 4. Prediction of reactivity to NIMA by MLR-ELISPOT assay. 
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5. Reactivity to mismatched histocompatibility antgens; Tolerogenic or 
immunogenic? 
The mechanisms by which NIMA drive the immune system toward tolerance or rejection of 
the allograft are still unclear. Although mismatch at MiHA can provoke severe immune 
responses against host cells upon transplantation (Goulmy, Schipper et al. 1996), the role of 
MiHA in the NIMA effects has not been described. Recently, naturally acquired tolerance 
and sensitization to MiHA have been reported (van Halteren, Jankowska-Gan et al. 2009). 
The presence of MiHA-specific Treg was shown in healthy adult women and men. In 
addition, it remains to be studied whether or not particular microchimeric cell types are 
associated with either a sensitized or a tolerized MiHA effect. Our study showed the 
difference of individual reactivities toward MHC, not MiHA, was critically influenced by 
the amount of MMc expression (Araki, Hirayama et al. 2010). The relationship between 
tolerogenic effect and MMc are consistent with a report of Dutta et al. They described the 
correlation between MMc and NIMA-specific Treg capable of suppressing both delayed 
type hypersensitivity and lymphoproliferative responses of effector T cells in a conventional 
NIMA mouse model (van Rood and Claas 1990; Andrassy, Kusaka et al. 2003). Opiela et al. 
described that transient exposure to low levels of NIMA alloantigens in early life may lead 
to long-term priming for both cytotoxic and helper T cell functions (Opiela, Levy et al. 2008). 
On the other hand, Aoyama et al. showed that both oral and in utero exposures to NIMA are 
required for the maximum induction of tolerance (Aoyama, Koyama et al. 2009). In any case, 
the mechanism underlying the development of tolerance versus priming to NIMA 
alloantigens remains to be clarified. 
6. Prediction of acute GVHD in mismatched HSCT 
Prediction of acute GVHD by in vitro assays prior to transplantation have not be very 
successful until now. In vitro detection of the frequencies of cytotoxic T-lymphocyte 
precursors (CTLp) and helper T-lymphocyte precursors (HTLp), in conjunction with MLR 
have been used as a method to detect individual reactivity to NIMA (Falkenburg, van 
Luxemburg-Heijs et al. 1996; Moretta, Locatelli et al. 1999; Tsafrir, Brautbar et al. 2000). 
Moretta et al. described that the frequency of NIMA-specific CTLp in cord blood samples 
were measured in order to better define the phenomenon of NIMA tolerance (Moretta, 
Locatelli et al. 1999). NIMA-reactive cord blood cells are detectable, but they were unable to 
detect differences between CTLp frequencies towards NIMA or NIPA. Falkenburg et al. 
investigated whether NIMA tolerance could allow transplantation over certain HLA 
barriers. Both CTLp and HTLp frequencies against NIPA were not statistically different than 
those directed against NIMA (Falkenburg, van Luxemburg-Heijs et al. 1996). Indeed, 
Kircher et al. showed that CTLp and HTLp frequencies were not predictive for the risk of 
acute GVHD in patients received allogeneic HSCT (Kircher, Niederwieser et al. 2004). 
Established test systems are therefore not available for the prediction of alloreactions and 
outcome after HSCT. Originally, it was predicted that CTLp reflects alloreactivity of class I 
mismatch, and HTLp reflect alloreactivity of class II mismatch. Levitsky et al. reported an 
evaluation of allogeneic reaction that used Treg (Levitsky, Miller et al. 2009). They generated 
carboxy-fluorescein diacetate succinimidyl ester-labeled CD4+CD25high FOXP3+ cells in 
MLR, which they called “Treg MLR”. These cells had varying HLA disparities and varying 
reactivities to cell components. However, this method reflects only a difference related to 
MHC class II. Thus, the above-mentioned methods can detect MHC class I or class II 
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separately, but it is difficult to detect them simultaneously. Recently, we reported a novel 
method, MLR-ELISPOT, to overcome these difficulties, as shown in Table 3. 
Assay Target antigen References 
Frequency of CTLp MHC class I 
(Hadley et al. 1990; Falkenburg et al. 1996; 
Moretta et al. 1999) 
Frequency of HTLp MHC class II (Falkenburg et al. 1996; Kircher et al. 2004) 
MLR, modified MLR MHC class II (Tsafrir, Brautbar et al. 2000) 
Treg MLR MHC class II (Levitsky, Miller et al. 2009) 
MLR-ELISPOT for IFN-γ MHC class I and II 
(MiHA) 
(Araki, Hirayama et al. 2010) 
Table 3. Detection assay to allogeneic antigen 
Alloreactivity of NIMA-exposed mice and NIMA-nonexposed mice were evaluated by MLR, 
and we found quite wider range of reactivity in the former compared with the latter. This 
helps to indicate that feto-maternal interaction acts on both tolerance (low responder) and 
sensitization (high responder) (Molitor-Dart, Andrassy et al. 2008; van Halteren, Jankowska-
Gan et al. 2009). The reports from Tsafrir et al. and Falkenburg et al. detected a reactivity to 
NIMA by MLR (Falkenburg, van Luxemburg-Heijs et al. 1996), and CTLp and HTLp 
(Tsafrir, Brautbar et al. 2000), respectively. Interestingly, when we scrutinized the figures in 
their articles, individual reactivities of NIMA-exposed group showed a wider range than the 
control group, and those reactivities seem to be divided into low and high reactions, 
although they did not discuss these observations. This was further indication that reactivity 
to NIMA could be detected in vitro, and the condition of feto-maternal interaction promoted 
either tolerance (low-responder) or sensitization (high-responder). 
Several investigators have reported that evaluations of reactivity to NIMA can be assessed, 
but the clinical relevance remains unknown. Presence of feto-maternal tolerance was 
anticipated due to MMc (Andrassy, Kusaka et al. 2003), and this concept has been used in 
clinical studies (Ichinohe, Maruya et al. 2002). Functional importance of MMc in humans has 
been further studied (Carter, Cerundolo et al. 1999; Cho, Choi et al. 2006). The majority of 
assays used to detect donor-derived cells in a recipient’s blood exploit sex-mismatch 
between donor and recipient or the polymorphism of the HLA-DR region of the MHC, 
determined with sequence specific primer PCR (SSP-PCR). SSP-PCR is commonly used for 
HLA typing the extent of match between donors and recipients prior to transplantation, but 
may not work well for detection of MMc. The sensitivity of detection of this technique can 
range from 0.5% to 0.01%, more than adequate for routine HLA-typing, but MMc levels may 
be from 0.01% to 0.001%, well below the sensitivity of the assay. Therefore, the sensitivity of 
SSP-PCR for HLA-DR alleles has been increased by the introduction of a nested priming of 
exon 2 SSP-PCR approached. Most of NIMA-mismatched haploidentical HSCT in Japan 
require positive MMc of the donor by using the nested SSP-PCR (Ichinohe, Maruya et al. 
2002; Carter, Cerundolo et al. 1999). 
Although detection of MMc was clinically used for an indication of probable tolerance to 
NIMA, severe acute cases of GVHD developed (Okumura, Yamaguchi et al. 2007; Kanda, 
Ichinohe et al. 2009). Studies indicate that NIMA allografts do better than NIPA allografts in 
vivo (Burlingham, Grailer et al. 1998), and in vitro T-cell responses to NIMA are 
significantly reduced in IL-2 and IFN-γ production assays, compared with NIPA (Andrassy, 
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Kusaka et al. 2003). Tsafrir et al. demonstrated this NIMA effect using umbilical cord blood 
mononuclear cells by a MLR assay (Tsafrir, Brautbar et al. 2000), but Hadley et al. could not 
detect the NIMA effect using peripheral blood mononuclear cells from healthy individuals 
(Hadley, Phelan et al. 1990). Thus, there is not a useful method to predict a tolerogenic effect 
for NIMA, although these studies may suggest that newborns are more tolerogenic to NIMA 
than older individuals. Recently, we demonstrated that the level of cells producing IFN-γ, 
but not IL-4 and IL-10, were significantly lower in NIMA-exposed group than NIMA-
nonexposed group by using an MLR-ELISPOT assay in a murine model (Araki, Hirayama et 
al. 2010) (Figure 4). This assay should be easily applicable to humans, and is a versatile 
method to detect reactivities to MHC class I as well as class II. And, it may also detect 
reactivity to MiHA (Table 3). In other words, this assay might be useful to predict the total 
immunological reaction of donor T cells to recipient in mismatched HSCT. 
7. Conclusions 
The risk of acute GVHD might be influenced by various genetic factors HLA, MiHA, or 
others (Hsu, Chida et al. 2002; Lin, Storer et al. 2003). NIMA-mismatched haploidentical 
HSCT has been improving with sustained engraftment, lower early treatment-related 
mortality, and acceptable rates of GVHD. However, it has been difficult to predict severe 
GVHD prior to transplantation. Our recent report has addressed the issue (Araki, Hirayama 
et al. 2010; Hirayama and Azuma 2011). NIMA effects directed toward MHC antigen were 
divided into high (immunogenic) and low (tolerogenic) reactivities. Our results in mice 
demonstrated that there was an unevenness in the acquisition and maintenance of MMc in 
the offspring. Further differential inheritance of MiHA did not influence our results, i.e., the 
variability amongst offspring was not due to solely to differences in MiHA gene inheritance. 
The variability seemed intrinsic to chance events in mammalian reproduction; i.e. allogeneic 
pregnancy and nursing itself (Aoyama, Koyama et al. 2009; Dutta, Molitor-Dart et al. 2009). 
To date, T-cell replete haploidentical transplantation is performed only in the presence of 
detected MMc in the recipient, although individual reactivity of donor to the receipient has 
not been evaluated. Could the pairing result in a low-responder/tolergenic or high-
responder/immunogenic situation? Therefore, our recent study is clinically relevant. T-cell 
replete NIMA-mismatched haploidentical transplantation could be performed more safely 
by using our assay to evaluate IFN-γ-producing cells of donor against NIMA as a way to 
further reduce graft failure, prevent transplant mortality, and prevent severe GVHD. 
8. Acknowledgments 
This study was supported in part by a Research Grant for Tissue Engineering (H17-014) and 
a Research Grant for Allergic Disease and Immunology (H20-015) from the Japanese 
Ministry of Health, Labor, and Welfare. 
9. References 
Akatsuka, Y., T. Nishida, et al. (2003). Identification of a polymorphic gene, BCL2A1, 
encoding two novel hematopoietic lineage-specific minor histocompatibility 
antigens.The Journal of experimental medicine 197(11): 1489-1500. 
www.intechopen.com
 
Major and Minor Histocompatibility Antigens to Non-Inherited Maternal Antigens (NIMA) 
 
157 
Aluvihare, V. R., M. Kallikourdis, et al. (2004). Regulatory T cells mediate maternal tolerance 
to the fetus.Nat Immunol 5(3): 266-271. 
Amos, D. B. (1968). Human histocompatibility locus HL-A.Science 159(815): 659-660. 
Andrassy, J., S. Kusaka, et al. (2003). Tolerance to noninherited maternal MHC antigens in 
mice.J Immunol 171(10): 5554-5561. 
Aoyama, K., M. Koyama, et al. (2009). Improved outcome of allogeneic bone marrow 
transplantation due to breastfeeding-induced tolerance to maternal antigens.Blood 
113(8): 1829-1833. 
Araki, M., M. Hirayama, et al. (2010). Prediction of reactivity to noninherited maternal 
antigen in MHC-mismatched, minor histocompatibility antigen-matched stem cell 
transplantation in a mouse model.J Immunol 185(12): 7739-7745. 
Aversa, F., A. Tabilio, et al. (1994). Successful engraftment of T-cell-depleted haploidentical 
"three-loci" incompatible transplants in leukemia patients by addition of 
recombinant human granulocyte colony-stimulating factor-mobilized peripheral 
blood progenitor cells to bone marrow inoculum.Blood 84(11): 3948-3955. 
Aversa, F., A. Terenzi, et al. (2005). Full haplotype-mismatched hematopoietic stem-cell 
transplantation: a phase II study in patients with acute leukemia at high risk of 
relapse.J Clin Oncol 23(15): 3447-3454. 
Beatty, P. G., C. Anasetti, et al. (1993). Marrow transplantation from unrelated donors for 
treatment of hematologic malignancies: effect of mismatching for one HLA 
locus.Blood 81(1): 249-253. 
Bleakley, M., B. E. Otterud, et al. (2010). Leukemia-associated minor histocompatibility 
antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ 
T cells.Blood 115(23): 4923-4933. 
Brickner, A. G., A. M. Evans, et al. (2006). The PANE1 gene encodes a novel human minor 
histocompatibility antigen that is selectively expressed in B-lymphoid cells and B-
CLL.Blood 107(9): 3779-3786. 
Brickner, A. G., E. H. Warren, et al. (2001). The immunogenicity of a new human minor 
histocompatibility antigen results from differential antigen processing.The Journal of 
experimental medicine 193(2): 195-206. 
Buckley, R. H., S. E. Schiff, et al. (1999). Hematopoietic stem-cell transplantation for the 
treatment of severe combined immunodeficiency.N Engl J Med 340(7): 508-516. 
Burlingham, W. J., A. P. Grailer, et al. (1998). The effect of tolerance to noninherited maternal 
HLA antigens on the survival of renal transplants from sibling donors.N Engl J Med 
339(23): 1657-1664. 
Carter, A. S., L. Cerundolo, et al. (1999). Nested polymerase chain reaction with sequence-
specific primers typing for HLA-A, -B, and -C alleles: detection of microchimerism 
in DR-matched individuals.Blood 94(4): 1471-1477. 
Cho, B. S., H. B. Choi, et al. (2006). Typing by nested PCR-SSP approach raises a question 
about the feasibility of using this technique for detecting feto-maternal 
microchimerism.Leukemia 20(5): 896-898. 
Choi, E. Y., Y. Yoshimura, et al. (2001). Quantitative analysis of the immune response to 
mouse non-MHC transplantation antigens in vivo: the H60 histocompatibility 
antigen dominates over all others.Journal of immunology 166(7): 4370-4379. 
Claas, F. H., Y. Gijbels, et al. (1988). Induction of B cell unresponsiveness to noninherited 
maternal HLA antigens during fetal life.Science 241(4874): 1815-1817. 
www.intechopen.com
 
Histocompatibility 
 
158 
de Rijke, B., A. van Horssen-Zoetbrood, et al. (2005). A frameshift polymorphism in P2X5 
elicits an allogeneic cytotoxic T lymphocyte response associated with remission of 
chronic myeloid leukemia.The Journal of clinical investigation 115(12): 3506-3516. 
den Haan, J. M., N. E. Sherman, et al. (1995). Identification of a graft versus host disease-
associated human minor histocompatibility antigen.Science 268(5216): 1476-1480. 
Dolstra, H., H. Fredrix, et al. (1999). A human minor histocompatibility antigen specific for B 
cell acute lymphoblastic leukemia.The Journal of experimental medicine 189(2): 301-308. 
Dutta, P., M. Molitor-Dart, et al. (2009). Microchimerism is strongly correlated with 
tolerance to noninherited maternal antigens in mice.Blood 114(17): 3578-3587. 
Eden, P. A., G. J. Christianson, et al. (1999). Biochemical and immunogenetic analysis of an 
immunodominant peptide (B6dom1) encoded by the classical H7 minor 
histocompatibility locus.Journal of immunology 162(8): 4502-4510. 
Falkenburg, J. H., S. A. van Luxemburg-Heijs, et al. (1996). Umbilical cord blood contains 
normal frequencies of cytotoxic T-lymphocyte precursors (ctlp) and helper T-
lymphocyte precursors against noninherited maternal antigens and noninherited 
paternal antigens.Ann Hematol 72(4): 260-264. 
Goulmy, E., R. Schipper, et al. (1996). Mismatches of minor histocompatibility antigens 
between HLA-identical donors and recipients and the development of graft-versus-
host disease after bone marrow transplantation.N Engl J Med 334(5): 281-285. 
Greenfield, A., D. Scott, et al. (1996). An H-YDb epitope is encoded by a novel mouse Y 
chromosome gene.Nature genetics 14(4): 474-478. 
Griffioen, M., E. D. van der Meijden, et al. (2008). Identification of phosphatidylinositol 4-
kinase type II beta as HLA class II-restricted target in graft versus leukemia 
reactivity.Proceedings of the National Academy of Sciences of the United States of America 
105(10): 3837-3842. 
Guinan, E. C., V. A. Boussiotis, et al. (1999). Transplantation of anergic histoincompatible 
bone marrow allografts.N Engl J Med 340(22): 1704-1714. 
Hadley, G. A., D. Phelan, et al. (1990). Lack of T-cell tolerance of noninherited maternal HLA 
antigens in normal humans.Hum Immunol 28(4): 373-381. 
Hall, J. M., P. Lingenfelter, et al. (1995). Detection of maternal cells in human umbilical cord 
blood using fluorescence in situ hybridization.Blood 86(7): 2829-2832. 
Henslee-Downey, P. J., S. H. Abhyankar, et al. (1997). Use of partially mismatched related 
donors extends access to allogeneic marrow transplant.Blood 89(10): 3864-3872. 
Hirayama, M. and E. Azuma (2011). Major and minor histocompatibility antigens to NIMA: 
Prediction of a tolerogenic NIMA effect.Chimerism 2(1): 23-24. 
Hsu, K. C., S. Chida, et al. (2002). The killer cell immunoglobulin-like receptor (KIR) 
genomic region: gene-order, haplotypes and allelic polymorphism.Immunol Rev 
190: 40-52. 
Huang, X. J., D. H. Liu, et al. (2009). Treatment of acute leukemia with unmanipulated HLA-
mismatched/haploidentical blood and bone marrow transplantation.Biol Blood 
Marrow Transplant 15(2): 257-265. 
Ichinohe, T., E. Maruya, et al. (2002). Long-term feto-maternal microchimerism: nature's 
hidden clue for alternative donor hematopoietic cell transplantation?Int J Hematol 
76(3): 229-237. 
Ichinohe, T., T. Uchiyama, et al. (2004). Feasibility of HLA-haploidentical hematopoietic 
stem cell transplantation between noninherited maternal antigen (NIMA)-
mismatched family members linked with long-term fetomaternal 
microchimerism.Blood 104(12): 3821-3828. 
www.intechopen.com
 
Major and Minor Histocompatibility Antigens to Non-Inherited Maternal Antigens (NIMA) 
 
159 
Kamei, M., Y. Nannya, et al. (2009). HapMap scanning of novel human minor 
histocompatibility antigens.Blood 113(21): 5041-5048. 
Kanda, J., T. Ichinohe, et al. (2009). Long-term survival after HLA-haploidentical SCT from 
noninherited maternal antigen-mismatched family donors: impact of chronic 
GVHD.Bone Marrow Transplant 44(5): 327-329.Kawase, T., Y. Akatsuka, et al. (2007). 
Alternative splicing due to an intronic SNP in HMSD generates a novel minor 
histocompatibility antigen.Blood 110(3): 1055-1063. 
Kircher, B., D. Niederwieser, et al. (2004). No predictive value of cytotoxic or helper T-cell 
precursor frequencies for outcome when analyzed from the graft after stem cell 
transplantation.Ann Hematol 83(9): 566-572. 
Kodera, Y., T. Nishida, et al. (2005). Human leukocyte antigen haploidentical hematopoietic 
stem cell transplantation: indications and tentative outcomes in Japan.Semin 
Hematol 42(2): 112-118. 
Levitsky, J., J. Miller, et al. (2009). The human "Treg MLR": immune monitoring for FOXP3+ 
T regulatory cell generation.Transplantation 88(11): 1303-1311. 
Lin, M. T., B. Storer, et al. (2003). Relation of an interleukin-10 promoter polymorphism to 
graft-versus-host disease and survival after hematopoietic-cell transplantation.N 
Engl J Med 349(23): 2201-2210. 
Lo, Y. M., E. S. Lo, et al. (1996). Two-way cell traffic between mother and fetus: biologic and 
clinical implications.Blood 88(11): 4390-4395. 
Lu, D. P., L. Dong, et al. (2006). Conditioning including antithymocyte globulin followed by 
unmanipulated HLA-mismatched/haploidentical blood and marrow 
transplantation can achieve comparable outcomes with HLA-identical sibling 
transplantation.Blood 107(8): 3065-3073. 
Luedtke, B., L. M. Pooler, et al. (2003). A single nucleotide polymorphism in the Emp3 gene 
defines the H4 minor histocompatibility antigen.Immunogenetics 55(5): 284-295. 
Malarkannan, S., T. Horng, et al. (2000). Differences that matter: major cytotoxic T cell-
stimulating minor histocompatibility antigens.Immunity 13(3): 333-344. 
Maloney, S., A. Smith, et al. (1999). Microchimerism of maternal origin persists into adult 
life.J Clin Invest 104(1): 41-47. 
Markiewicz, M. A., C. Girao, et al. (1998). Long-term T cell memory requires the surface 
expression of self-peptide/major histocompatibility complex molecules.Proceedings 
of the National Academy of Sciences of the United States of America 95(6): 3065-3070. 
Matsuoka, K., T. Ichinohe, et al. (2006). Fetal tolerance to maternal antigens improves the 
outcome of allogeneic bone marrow transplantation by a CD4+ CD25+ T-cell-
dependent mechanism.Blood 107(1): 404-409. 
Mehta, J., S. Singhal, et al. (2004). Bone marrow transplantation from partially HLA-
mismatched family donors for acute leukemia: single-center experience of 201 
patients.Bone Marrow Transplant 33(4): 389-396. 
Mendoza, L. M., P. Paz, et al. (1997). Minors held by majors: the H13 minor histocompatibility 
locus defined as a peptide/MHC class I complex.Immunity 7(4): 461-472. 
Mendoza, L. M., G. Villaflor, et al. (2001). Distinguishing self from nonself: immunogenicity 
of the murine H47 locus is determined by a single amino acid substitution in an 
unusual peptide.Journal of immunology 166(7): 4438-4445. 
Molitor-Dart, M. L., J. Andrassy, et al. (2008). Tolerance induction or sensitization in mice 
exposed to noninherited maternal antigens (NIMA).Am J Transplant 8(11): 2307-2315. 
www.intechopen.com
 
Histocompatibility 
 
160 
Mommaas, B., J. Kamp, et al. (2002). Identification of a novel HLA-B60-restricted T cell 
epitope of the minor histocompatibility antigen HA-1 locus.Journal of immunology 
169(6): 3131-3136. 
Moretta, A., F. Locatelli, et al. (1999). Characterisation of CTL directed towards non-
inherited maternal alloantigens in human cord blood.Bone Marrow Transplant 
24(11): 1161-1166. 
Murata, M., E. H. Warren, et al. (2003). A human minor histocompatibility antigen resulting 
from differential expression due to a gene deletion.The Journal of experimental 
medicine 197(10): 1279-1289. 
O'Reilly, R. J., C. Keever, et al. (1987). HLA nonidentical T cell depleted marrow transplants: 
a comparison of results in patients treated for leukemia and severe combined 
immunodeficiency disease.Transplant Proc 19(6 Suppl 7): 55-60. 
Okumura, H., M. Yamaguchi, et al. (2007). Graft rejection and hyperacute graft-versus-host 
disease in stem cell transplantation from non-inherited maternal-antigen-
complementary HLA-mismatched siblings.Eur J Haematol 78(2): 157-160. 
Opiela, S. J., R. B. Levy, et al. (2008). Murine neonates develop vigorous in vivo cytotoxic 
and Th1/Th2 responses upon exposure to low doses of NIMA-like 
alloantigens.Blood 112(4): 1530-1538. 
Owen, R. D., H. R. Wood, et al. (1954). EVIDENCE FOR ACTIVELY ACQUIRED 
TOLERANCE TO Rh ANTIGENS.Proc Natl Acad Sci U S A 40(6): 420-424. 
Perreault, C., J. Jutras, et al. (1996). Identification of an immunodominant mouse minor 
histocompatibility antigen (MiHA). T cell response to a single dominant MiHA 
causes graft-versus-host disease.The Journal of clinical investigation 98(3): 622-628. 
Petersdorf, E. W., G. M. Longton, et al. (1995). The significance of HLA-DRB1 matching on 
clinical outcome after HLA-A, B, DR identical unrelated donor marrow 
transplantation.Blood 86(4): 1606-1613. 
Pierce, R. A., E. D. Field, et al. (1999). Cutting edge: the HLA-A*0101-restricted HY minor 
histocompatibility antigen originates from DFFRY and contains a cysteinylated 
cysteine residue as identified by a novel mass spectrometric technique.Journal of 
immunology 163(12): 6360-6364. 
Reisner, Y., N. Kapoor, et al. (1981). Transplantation for acute leukaemia with HLA-A and B 
nonidentical parental marrow cells fractionated with soybean agglutinin and sheep 
red blood cells.Lancet 2(8242): 327-331. 
Rizzieri, D. A., L. P. Koh, et al. (2007). Partially matched, nonmyeloablative allogeneic 
transplantation: clinical outcomes and immune reconstitution.J Clin Oncol 25(6): 
690-697. 
Roopenian, D., E. Y. Choi, et al. (2002). The immunogenomics of minor histocompatibility 
antigens.Immunol Rev 190: 86-94. 
Sahara, H. and N. Shastri (2003). Second class minors: molecular identification of the 
autosomal H46 histocompatibility locus as a peptide presented by major 
histocompatibility complex class II molecules.The Journal of experimental medicine 
197(3): 375-385. 
Sanderson, C. J. and P. Frost (1974). The induction of tumour immunity in mice using 
glutaraldehyde-treated tumor cells.Nature 248(450): 690-691. 
Scott, D., C. Addey, et al. (2000). Dendritic cells permit identification of genes encoding MHC 
class II-restricted epitopes of transplantation antigens.Immunity 12(6): 711-720. 
www.intechopen.com
 
Major and Minor Histocompatibility Antigens to Non-Inherited Maternal Antigens (NIMA) 
 
161 
Sellami, M. H., H. Kaabi, et al. (2011). Minor histocompatibility antigens in Tunisians: could 
platelet endothelial cell adhesion molecule 1 marker be one of them?Tissue antigens 
77(1): 68-73. 
Slager, E. H., M. W. Honders, et al. (2006). Identification of the angiogenic endothelial-cell 
growth factor-1/thymidine phosphorylase as a potential target for immunotherapy 
of cancer.Blood 107(12): 4954-4960. 
Spaapen, R. M., R. A. de Kort, et al. (2009). Rapid identification of clinical relevant minor 
histocompatibility antigens via genome-wide zygosity-genotype correlation 
analysis.Clinical cancer research : an official journal of the American Association for 
Cancer Research 15(23): 7137-7143. 
Spaapen, R. M., H. M. Lokhorst, et al. (2008). Toward targeting B cell cancers with CD4+ 
CTLs: identification of a CD19-encoded minor histocompatibility antigen using a 
novel genome-wide analysis.The Journal of experimental medicine 205(12): 2863-2872. 
Spierings, E., A. G. Brickner, et al. (2003). The minor histocompatibility antigen HA-3 arises 
from differential proteasome-mediated cleavage of the lymphoid blast crisis (Lbc) 
oncoprotein.Blood 102(2): 621-629. 
Spierings, E., C. J. Vermeulen, et al. (2003). Identification of HLA class II-restricted H-Y-
specific T-helper epitope evoking CD4+ T-helper cells in H-Y-mismatched 
transplantation.Lancet 362(9384): 610-615. 
Stern, M., J. R. Passweg, et al. (2006). Influence of donor/recipient sex matching on outcome 
of allogeneic hematopoietic stem cell transplantation for aplastic 
anemia.Transplantation 82(2): 218-226. 
Stumpf, A. N., E. D. van der Meijden, et al. (2009). Identification of 4 new HLA-DR-
restricted minor histocompatibility antigens as hematopoietic targets in antitumor 
immunity.Blood 114(17): 3684-3692. 
Torikai, H., Y. Akatsuka, et al. (2006). The human cathepsin H gene encodes two novel 
minor histocompatibility antigen epitopes restricted by HLA-A*3101 and -
A*3303.British journal of haematology 134(4): 406-416. 
Torikai, H., Y. Akatsuka, et al. (2004). A novel HLA-A*3303-restricted minor 
histocompatibility antigen encoded by an unconventional open reading frame of 
human TMSB4Y gene.Journal of immunology 173(11): 7046-7054. 
Tsafrir, A., C. Brautbar, et al. (2000). Alloreactivity of umbilical cord blood mononuclear cells: 
specific hyporesponse to noninherited maternal antigens.Hum Immunol 61(6): 548-554. 
Tykodi, S. S., N. Fujii, et al. (2008). C19orf48 encodes a minor histocompatibility antigen 
recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.Clinical 
cancer research : an official journal of the American Association for Cancer Research 
14(16): 5260-5269. 
van Bergen, C. A., M. G. Kester, et al. (2007). Multiple myeloma-reactive T cells recognize an 
activation-induced minor histocompatibility antigen encoded by the ATP-
dependent interferon-responsive (ADIR) gene.Blood 109(9): 4089-4096. 
Van Bergen, C. A., C. E. Rutten, et al. (2010). High-throughput characterization of 10 new 
minor histocompatibility antigens by whole genome association scanning.Cancer 
research 70(22): 9073-9083. 
van Halteren, A. G., E. Jankowska-Gan, et al. (2009). Naturally acquired tolerance and 
sensitization to minor histocompatibility antigens in healthy family members.Blood 
114(11): 2263-2272. 
van Rood, J. J. and F. H. Claas (1990). The influence of allogeneic cells on the human T and B 
cell repertoire.Science 248(4961): 1388-1393. 
www.intechopen.com
 
Histocompatibility 
 
162 
van Rood, J. J., F. R. Loberiza, Jr., et al. (2002). Effect of tolerance to noninherited maternal 
antigens on the occurrence of graft-versus-host disease after bone marrow 
transplantation from a parent or an HLA-haploidentical sibling.Blood 99(5): 1572-1577. 
Verdijk, R. M., A. Kloosterman, et al. (2004). Pregnancy induces minor histocompatibility 
antigen-specific cytotoxic T cells: implications for stem cell transplantation and 
immunotherapy.Blood 103(5): 1961-1964. 
Verhasselt, V., V. Milcent, et al. (2008). Breast milk-mediated transfer of an antigen induces 
tolerance and protection from allergic asthma.Nat Med 14(2): 170-175. 
Vogt, M. H., E. Goulmy, et al. (2000). UTY gene codes for an HLA-B60-restricted human 
male-specific minor histocompatibility antigen involved in stem cell graft rejection: 
characterization of the critical polymorphic amino acid residues for T-cell 
recognition.Blood 96(9): 3126-3132. 
Wang, W., L. R. Meadows, et al. (1995). Human H-Y: a male-specific histocompatibility 
antigen derived from the SMCY protein.Science 269(5230): 1588-1590. 
Warren, E. H., N. J. Vigneron, et al. (2006). An antigen produced by splicing of 
noncontiguous peptides in the reverse order.Science 313(5792): 1444-1447. 
Yang, J., A. Jaramillo, et al. (2003). Chronic rejection of murine cardiac allografts discordant 
at the H13 minor histocompatibility antigen correlates with the generation of the 
H13-specific CD8+ cytotoxic T cells.Transplantation 76(1): 84-91. 
Zorn, E., D. B. Miklos, et al. (2004). Minor histocompatibility antigen DBY elicits a 
coordinated B and T cell response after allogeneic stem cell transplantation.The 
Journal of experimental medicine 199(8): 1133-1142. 
Zuberi, A. R., G. J. Christianson, et al. (1998). Positional cloning and molecular 
characterization of an immunodominant cytotoxic determinant of the mouse H3 
minor histocompatibility complex.Immunity 9(5): 687-698. 
www.intechopen.com
Histocompatibility
Edited by Dr. Bahaa Abdel-Salam
ISBN 978-953-51-0589-3
Hard cover, 188 pages
Publisher InTech
Published online 02, May, 2012
Published in print edition May, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book presents some recent researches related to histocompatibility for scientists interested in this field. It
includes 10 chapters, in different topics, prepared by Sundararajulu Panneerchelvam and Mohd Nor Norazmi;
Giada Amodio and Silvia Gregori; Adema Ribic; Bahaa K. A. Abdel-Salam; Kai-Fu Tang; Roberto Biassoni,
Irene Vanni and Elisabetta Ugolotti; Wei-Cheng Yang, Lien-Siang Chou and Jer-Ming Hu; Shatrah Othman and
Rohana Yusof; Masahiro Hirayama, Eiichi Azuma and Yoshihiro Komada; Gustav Roder, Linda Geironson,
Elna Follin, Camilla Thuring and Kajsa Paulsson.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Masahiro Hirayama, Eiichi Azuma and Yoshihiro Komada (2012). Major and Minor Histocompatibility Antigens
to Non-Inherited Maternal Antigens (NIMA), Histocompatibility, Dr. Bahaa Abdel-Salam (Ed.), ISBN: 978-953-
51-0589-3, InTech, Available from: http://www.intechopen.com/books/histocompatibility/major-and-minor-
histocompatibility-antigens-to-non-inherited-maternal-antigens
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
